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Natural neurosteroids and synthetic steroids
Neurosteroids (NS), a term proposed by the physiologists 
Baulieu and Robel (1990), is widely used to refer to the ste-
roids synthesized in the brain. Through their interaction 
with neuronal membrane receptors and ion channels, they 
are capable to modify the brain excitability (Lambert et al., 
2003; Akk et al., 2009). Depending on its chemical struc-
ture, the steroids interactions with the GABAA receptor may 
produce positive or negative modulations (Majewska, 1992; 
Reddy, 2003). Among the positive modulators of this recep-
tor are two progesterone’s metabolites: the 5α-pregnane-3α-
ol-20-one (allopregnanolone) and its isomer 5α-pregnane-
3β-ol-20-one (pregnanolone; Gasior et al., 1999). The 
interest on these steroids arises from their potential activity 
as anticonvulsants, anesthetics, anxiolytic or sedative-hyp-
notic agents (Akk et al., 2007) useful for the treatment of 
several neurological and psychiatric disorders (Gasior et al., 
1999). Also, various physiological and pathophysiological 
conditions have been associated with changes in allopreg-
nanolone and pregnanolone levels (Akk et al., 2007). 
Although the natural NS can be used in epileptic patients 
(Herzog, 1999), certain properties, like their short biological 
half-life, avoid their clinical use. For that reason, synthetic 
steroids (SS), that exhibit better bioavailability and efficacy, 
have an important therapeutic potential in brain disorders, 
becoming an alternative for this kind of pathologies (Reddy 
and Kulkarni, 2000; Morrow, 2007). 
Therefore, there is a considerable interest around NS phys-
iology and synthetic analogues development. The medicinal 
chemistry of neuroactive steroids (NAS) has been focused 
in the development of SS analogues preserving the absolute 
configuration of naturally occurring steroids. Structure/
activity studies indicate that the 3α-hydroxyl configuration 
is required for binding and activity (Purdy et al., 1990). 
However, modifications of the steroid nucleus may empha-
size different pharmacophores. For example, the 3β-meth-
ylated synthetic analog of allopregnanolone, ganaxolone 
(3α-hydroxy-3β-methyl-5α-prengan-20-one) is capable to 
overcome these limitations, showing effective anticonvulsant 
properties (Carter et al., 1997; Reddy and Woodward, 2004). 
In fact, until now, it is the only SS that has been proved in 
human clinical trials for epilepsy (Nohria et al., 2010). 
Neurosteroids and GABAA receptor function
GABA binding to its receptor gates an intrinsic anion-se-
lective channel. According to the reversal potential of the 
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permeate ions, the postsynaptic GABA response can be 
excitatory or inhibitory (Akk et al., 2007). The binding of 
the convulsant t-butyl-bicyclophosphorothionate (TBPS) 
to the GABAA receptor can be allosterically modulated by 
allopregnanolone and pregnanolone (Ramanjaneyulu and 
Ticku, 1984). When GABA is present, these metabolites have 
a significantly increased binding affinity, and under this 
condition, it is possible to reflect the functional state of this 
receptor (Majewska, 1992; Hawkinson et al., 1994). Similar-
ly, NAS can also stimulate the binding of flunitrazepam or 
muscimol to the receptor (Majewska et al., 1986; Hawkinson 
et al., 1994). The NS exposure enhances the opening proba-
bility of the chloride channel, so that the mean time open is 
increased, resulting in a reduction of neuronal excitability. 
  Harrison and Simmons (1984) demonstrated that alphax-
alone (ALPX; 3α-hydroxy-5α-pregnane-11,20-dione), an-
other allopregnanolone synthetic analogue, was able to en-
hance the GABA-evoked responses. Also, a positive allosteric 
modulation of GABAA receptor was found with the SS ga-
naxolone (Carter et al., 1997; Gasior et al., 1997). Since then, 
several SS with different features have been developed. It has 
been described that at least two ent-16-ketosteroid synthetic 
analogues (3α-5α-androsten-16-one and 3α-5α-4methoxy-
androsten-16-one; with an absolute opposite configuration 
to NAS), produced a more potent inhibition of the TBPS 
binding than ALPX (Qian et al., 2013). Moreover, we showed 
a decrease in TBPS binding and an increase in flunitrazepam 
and muscimol binding by the administration of SS epoxies 
(analogues to allopregnanolone and pregnanolone) with an 
intramolecular oxygen bridge that keeps the A/B angle of 
the steroid nucleus in a controlled way (Veleiro and Burton, 
2009; Rey et al., 2013). 
NAS and SS neuroprotective role 
Cumulative evidence indicates the existence of neuropro-
tective properties of NAS in a variety of experimental par-
adigms (Schumacher et al., 2004). They have a major influ-
ence on the central nervous system (CNS) activity and are 
essential for growth and survival of neurons and glial cells 
(Wang et al., 2005; Melcangi et al., 2008). Studies in adult 
animals after brain injury indicate that NAS have an import-
ant role in repairing processes, enhancing myelination and 
reducing apoptotic processes (Ibanez et al., 2004). During 
pregnancy, stressful events which lead to transient hypoxia/
ischemia, stimulate NAS production in the brain providing 
further protection (Nguyen et al., 2004). This supports the 
importance of NAS in brain development and suggests that 
the exposure to normal NAS levels is critical. In traumat-
ic brain injury, progesterone has the most important re-
pair-promoting actions (He et al., 2004a) and it acts through 
its reduced metabolites like allopregnanolone (Djebaili et al., 
2004; He et al., 2004b; Ardeshiri et al., 2006). The neuropro-
tective actions of allopregnanolone have been shown in hy-
poxia-induced brain injury models, where its levels increase 
in response to acute hypoxic stress, as a protective mecha-
nism to reduce excitotoxicity (Hirst et al., 2006). In fact, we 
have described a protective effect of allopregnanolone on as-
trogliosis (Kruse et al., 2009) and neuronal damage (Kruse et 
al., 2010) caused by hypoxia in perinatal cultures of cerebral 
cortex and hippocampus of the rat. Studies with the SS mife-
pristone (RU486), reported that it acts as a neuroprotective 
agent against excitotoxicity and traumatic brain injury (Behl 
et al., 1997; McCullers et al., 2002) and protects Purkinje 
cells from cell death in postnatal rat and mouse cerebellum 
organotypic slice cultures (Ghoumari et al., 2003), through 
the reversion of chloride efflux in the GABAA receptor elicit-
ed by GABA (Rakotomamonjy et al., 2011). Other properties 
like antiprogestagen and antiglucorticoids, were observed 
with their administration. We have also demonstrated that 
two SS epoxies, (analogues of allopregnanolone and preg-
nanolone,) were capable to prevent the glial and neuronal 
damages in the perinatal cultures of cerebral cortex and hip-
pocampus (Rey et al., 2013). 
In adults, the brain ischemic stroke is also considered a 
hypoxic event that compromises the brain functionality. 
During ischemia, the loss of energy supply by the mitochon-
drial dysfunction and posterior increased oxidative stress 
contributed to the neuronal injury. Therefore, a trend has 
been set in the development of steroid drugs that reduce 
the excitotoxicity and the oxidative stress, for treatments of 
acute brain injuries or chronic neurodegenerative diseases. 
Because the current therapies are still limited the promotion 
of novel neuroprotectants is essential for the ischemic stroke 
treatment. One example is the SS 5α-androst-3β,5,6β-triol 
showed a robust neuroprotective effects when it was tested 
in vitro (Chen et al., 2013). 
The Alzheimer’s disease (AD) produces a brain degener-
ative process, with neuronal losses and decreased synapses. 
Present therapies are focused on stopping the progression of 
the disease, but the major challenge remains, in restore cog-
nitive function through the regeneration of lost neurons and 
neural circuitry. In aged and AD brains, the pool of neural 
stem cells, their proliferative potential and the allopregnano-
lone content are markedly diminished (Bernardi et al., 1998; 
Genazzani et al., 1998; Weill-Engerer et al., 2002). Studies 
using transgenic AD mice showed that allopregnanolone 
has neurogenic properties (Wang et al., 2008). These in vitro 
and in vivo neurogenic features, coupled to low molecular 
weight, easy blood brain barrier penetration and lack of 
toxicity, are the key elements required to consider the use 
of allopregnanolone as a neurogenic/regenerative therapy 
for neurons restoration in AD patients (Brinton and Wang, 
2006; Irwin and Brinton, 2014). Estrogen has also showed 
neuroprotective properties, preventing the development of 
neurodegenerative disorders like AD. Hormonal therapy at 
menopause (to restore normal levels) appears to reduce the 
risks, but this kind of treatment has been associated with 
detrimental effects. Therefore, the development of SS with 
a selective agonist action is promising. Moreover, estrogen 
like neuroprotection effects were observed with the SS 4-es-
tren-3α,17β-diol that differs structurally from estrogens only 
on the A ring (Kousteni et al., 2002; Cordey et al., 2005). In 
addition, similar neuroprotective actions have been described 
with the SS ent-steroid of 17β-estradiol (Covey, 2009). 
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Neurosteroids synthesis: steroid effects on 
3β-HSD activity 
Another important issue is the influence of the SS on the 
local natural NS synthesis. NAS are present in the nervous 
system and in other steroidogenic tissues, like gonads and 
adrenal glands. In the CNS, NS synthesis occurs in glial and 
neuronal cells. Within the mitochondrial matrix, the choles-
terol is converted to pregnenolone by the cytochrome P450 
side-chain cleavage enzyme (CYP450scc; Iwahashi et al., 
1990). Then, the pregnenolone is oxidized to progesterone 
by the 3β-hydroxysteroid dehydrogenase enzyme (3β-HSD; 
Zwain and Yen, 1999) being this conversion an essential 
step in the biosynthesis of all steroid hormones. Allopreg-
nanolone is synthesized from progesterone, by the sequen-
tial enzymatic steps of the type I 5α-reductase (5α-R) and 
the 3α-hydroxysteroid dehydrogenase enzymes (3α-HSD; 
Mellon et al., 2001). The rate-limiting step in neuroste-
roidogenesis is the unidirectional reduction of progesterone 
to the 5α-dihydroprogesterone (5α-DHP) by the 5α-R. Sub-
sequently, the 3α-HSD catalyzes conversion of 5α-DHP into 
allopregnanolone. Functionally expression of these enzymes 
has been described in pluripotent progenitor cells (Melcangi 
et al., 1996). 
On the other hand, the expression of 3β-HSD enzyme 
has been demonstrated in several tissues like adrenal 
glands, gonads and CNS (Rheaume et al., 1991; Guennoun 
et al., 1995; Coirini et al., 2003). Moreover, pregnenolone 
conversion into progesterone has been demonstrated in rat 
homogenates from septum and amygdala (Weinfeld et al., 
1980). The co-expression of 3β-HSD and GABAA recep-
tor subunits in different brain regions (Laurie et al., 1992; 
Wisden et al., 1992) gives an anatomo-functional support 
for the in situ production of progesterone and the GABAA 
receptor modulation (Guennoun et al., 1995). Although 
regulatory mechanisms underlying the NS biosynthesis in-
side the brain remain unclear, it is well known the capacity 
of steroids of negatively modulate the 3β-HSD activity in 
different steroidogenic endocrine glands and in peripheral 
nervous system, like sciatic nerve (Guennoun et al., 1995; 
Coirini et al., 2003). Among SS, the RU486 caused an im-
pact on the 3β-HSD enzyme activity in rat adrenal gland 
(Albertson et al., 1994) but not in gonads (Sanchez et al., 
1989). In our work, we described that SS epoxies caused a 
dose-dependent decrease on the 3β-HSD activity. In fact, 
the analogues of pregnanolone produced less inhibition 
than those with the conformation allopregnanolone-like 
(Rey et al., 2013).  
Conclusion
NS are endogenous regulators of neuronal excitability (Lam-
bert et al., 2003; Akk et al., 2009). Within the brain, reduced 
steroids (like allopregnanolone and pregnanolone) are highly 
selective and potent modulators of the GABAA receptor func-
tions (Gasior et al., 1999). Thus, their anticonvulsant, anes-
thetics and anxiolytic properties are useful in the treatment 
of several neurological and psychiatric disorders (Schüle et 
al., 2011). Neuroprotective effects against adverse early life 
events (Patchev et al., 1997) and neurogenic effects on neu-
rodegenerative diseases, like AD (Brinton and Wang, 2006), 
have been observed with allopregnanolone administration. 
Steroids with similar activity like this progesterone metabo-
lite provide big opportunities for therapeutic treatments re-
ducing hormonal side effects (Morrow, 2007; Reddy, 2010). 
The principal disadvantage of endogenous NS administra-
tion is their poor bioavailability caused by their rapid in vivo 
metabolism. Thus, endogenous NS stimulation synthesis or 
synthetic steroids analogues (Poisbeau et al., 2014) might 
constitute promising novel strategies for several disorders 
treatments. The current medicinal chemistry around NAS 
is focused on the development of new SS analogues, having 
the absolute configuration of natural steroids. Several stud-
ies indicate that the 3α-hydroxyl configuration is the key for 
binding and activity, but modifications in the steroid nucle-
us may emphasize different pharmacophores. Among the SS 
developed are ganaxolone and ALPX which have anesthetic 
and anticonvulsant properties. Until now, ganaxolone is 
the only one SS that has been used on human clinical trials 
for epilepsy (Nohria et al., 2010). On the other hand, the 
SS ent-neurosteroids produced more potent inhibition of 
TBPS binding from the GABAA receptor than ALPX (Qian 
et al., 2013). Moreover, we found that some SS epoxies re-
duce the TBPS binding and stimulate the flunitrazepam and 
muscimol binding in a dose-dependent manner (Rey et al., 
2013). On the other hand, anxiolytic effects are mediated by 
GABAA receptors (Reddy and Kulkarni, 1997). Therefore 
NS modulation of this receptor can be traduced in SS anxi-
olytic properties. This type of effects was observed with the 
synthetic allopregnanolone analogue Co 2-6749 (GMA-839; 
WAY-141839; 3α,21-dihydroxy-3β-trifluoromethyl-19-nor-
5β-pregnan-20-one; Vanover et al., 2000). In fact, neuroste-
roidogenic agents, that lack benzodiazepine-like side effects, 
are promising for the treatment of anxiety and depression 
(Reddy, 2010). 
Neuroprotective effects have been described with several 
SS in hypoxia-induced brain injury models. Among others, 
the SS RU486 was able to protect against excitotoxicity and 
traumatic brain injury (Behl et al., 1997; McCullers et al., 
2002) and the 5α-androst-3β,5,6β-triol showed a neuropro-
tective action in an ischemic stroke model in vitro (Chen et 
al., 2013). Moreover, in perinatal brain tissues submitted to 
hypoxic conditions, restricted analogues from allopregnano-
lone or pregnanolone showed similar properties preventing 
the glial and neuronal damage (Rey et al., 2013). On the oth-
er hand, neurogenic properties on AD were observed with 
the 4-estren-3α,17β-diol and ent-steroid of 17β-estradiol 
administrations (Kousteni et al., 2002; Covey, 2009). 
Another issue to take in consideration for the development 
of SS is related to the presence of all the enzymes necessary 
for NS synthesis in the brain (Mensah-Nyagan et al., 1999; 
Agis-Balboa et al., 2006; Do Rego et al., 2009). Although reg-
ulatory mechanisms around NS biosynthesis are still unclear, 
it is well known the capacity of steroids to negatively modu-
late the 3β-HSD activity (in almost all steroidogenic tissues) 
and the importance of a minor effect on these activities by 
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the SS administration.
Specific enzymes and nuclear hormone receptors for en-
dogenous steroids have structurally defined binding sites. 
It is important that the SS should be developed lacking the 
possibility to bind with high affinity to these proteins. There-
fore the SS drugs might not strongly interfere with the natu-
ral steroids biosynthesis or their specific receptors. It would 
be also advantageous that the half-life of these new SS might 
be quite different and potentially longer, than those of ste-
roid already used as anticonvulsants, anxiolytics, or another 
neuroactive-neurogenic agents. Thus, it is likely that the 
development of new SS for therapeutical use will continue 
requiring a great deal of effort with the attendant generation 
of new knowledge. 
Author contributions: MR was responsible for writing the 
first draft of the manuscript and contributed to its editing and 
revision. HC was responsible for the review conception, and 
contributed to the design of the manuscript, writing and edit-
ing. Both authors approved the final version of this review.
Conflicts of interest: None declared.
References
Agis-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Gui-
dotti A (2006) Characterization of brain neurons that express en-
zymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci U S A 
103:14602-14607.
Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S 
(2007) Mechanisms of neurosteroid interactions with GABAA recep-
tors. Pharmacol Ther 116:35-37.
Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S 
(2009) The influence of the membrane on neurosteroid actions at 
GABA(A) receptors. Psychoneuroendocrinology 34:S59-S66.
Albertson BD, Hill RB, Sprague KA, Wood KE, Nieman LK, Loriaux 
DL (1994) Effect of the antiglucocorticoid RU486 on adrenal ste-
roidogenic enzyme activity and steroidogenesis. Eur J Endocrinol 
130:195-200.
Ardeshiri A, Kelley MH, Korner IP, Hurn PD, Herson PS (2006) Mecha-
nism of progesterone neuroprotection of rat cerebellar Purkinje cells 
following oxygen-glucose deprivation. Eur J Neurosci 24:2567-2574.
Baulieu EE, Robel P (1990) Neurosteroids: a new brain function? J Ste-
roid Biochem Mol Biol 37:395-403.
Behl C, Trapp T, Skutella T, Holsboer F (1997) Protection against oxi-
dative stress-induced neuronal cell death-a novel role for RU486. Eur 
J Neurosci 9:912-920.
Bernardi F, Salvestroni C, Casarosa E, Nappi RE, Lanzone A, Luisi S, 
Purdy RH, Petraglia F, Genazzani AR (1998) Aging is associated with 
changes in allopregnanolone concentrations in brain, endocrine 
glands and serum in male rats. Eur J Endocrinol 138:316-321.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS 
(2010) Progress report on new antiepileptic drugs: a summary of the 
Tenth Eilat Conference (EILAT X). Epilepsy Res 92:89-124.
Brinto RD, Wang JM (2006) Preclinical analyses of the therapeutic po-
tential of allopregnanolone to promote neurogenesis in vitro and in 
vivo in transgenic mouse model of Alzheimer’s disease. Curr Alzhei-
mer Res 3:11-17. 
Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, 
White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, 
Gee KW (1997) Characterization of the anti convulsant properties of 
ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-preg-
nan-20-one), a selective, high-affinity, steroid modulator of the gam-
ma- aminobutyricacid (A) receptor. J Pharmacol Exp Ther 280:1284-
1295.
Chen J, Leng T, Chen W, Yan M, Yin W, Huang Y, Lin S, Duan D, Lin J, Wu 
G, Zhang J, Yan G (2013) A synthetic steroid 5α-androst-3β,5,6β-triol 
blocks hypoxia/reoxygenation-induced neuronal injuries via protec-
tion of mitochondrial function. Steroids 78:996-1002.
Coirini H, Gouézou M, Delespierre B, Liere P, Pianos A, Eychenne B, 
Schumacher M, Guennoun R (2003) Characterization and regulation 
of the 3β-hydroxysteroid dehydrogenase isomerase enzyme in the rat 
sciatic nerve. J Neurochem 84:119-126.
Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ (2005) The syn-
thetic estrogen 4-stren-3 alpha,17 beta-diol (estren) induces estro-
gen-like neuroprotection. Neurobiol Dis 19:331-339.
Covey DF (2009) ent-Steroids: novel tools for studies of signaling path-
ways. Steroids 74:577-585.
Djebaili M, Hoffman SW, Stein DG (2004) Allopregnanolone and pro-
gesterone decrease cell death and cognitive deficits after a contusion 
of the rat pre-frontal cortex. Neuroscience 123:349-359.
Do Rego JL, Seong JY, Burel D, Leprince J, Luu-The V, Tsutsui K, Tonon 
MC, Pelletier G, Vaudry H (2009) Neurosteroid biosynthesis: enzy-
matic pathways and neuroendocrine regulation by neurotransmitters 
and neuropeptides. Front Neuroendocrinol 30:259-301. 
Gasior M, Carter RB, Goldberg SR, Witkin JM (1997) Anticonvulsant 
and behavioral effects of neuroactive steroids alone and in conjunc-
tion with diazepam. J Pharmacol Exp Ther 282:543-553.
Gasior M, Carter RB, Witkin JM (1999) Neuroactive steroids: potential 
therapeutic use in neurological and psychiatric disorders. Trends 
Pharmacol Sci 20:107-111.
Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti 
A, Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M (1998) Circu-
lating levels of allopregnanolone in humans: gender, age, and endo-
crine influences. J Clin Endocrinol Metab 83:2099-2103.
Ghoumari AM, Dusart I, El-Etr M, Tronche F, Sotelo C, Schumacher M, 
Baulieu EE (2003) Mifepristone (RU486) protects Purkinje cells from 
cell death in organotypic slice cultures of postnatal rat and mouse 
cerebellum. Proc Natl Acad Sci U S A 100:7953-7958. 
Guennoun R, Fiddes RJ, Gouézou M, Lombès M, Baulieu EE (1995) A 
key enzyme in the biosynthesis of neurosteroids; 3β-hydroxysteroid 
dehydrogenase/Δ5–Δ4-isomerase (3β-HSD) is expressed in rat brain. 
Brain Res Mol Brain Res 30:287-300.
Harrison NL, Simmonds MA (1984) Modulation of the GABA receptor 
complex by a steroid anaesthetic. Brain Res 323:287-292.
Hawkinson JE, Kimbrough CL, Belelli D, Lambert JJ, Prurdy RH, Lan 
NC (1994) Correlation of neuroactive steroid modulation of [35S]
t-butylbicyclophosphorothionate and [3H]-flunitrazepam binding 
and gamma-aminobutyric acid receptor function. Mol Pharmacol 
46:977-985.
He J, Evans  O, Hoffman SW, Oyesiku NM, Stein DG (2004a) Proges-
terone and allopregnanolone reduce inflammatory cytokines after 
traumatic brain injury. Exp Neurol 189:404-412.
He J, Hoffman SW, Stein DG (2004b) Allopregnanolone, a progesterone 
metabolite, enhances behavioral recovery and decreases neuronal 
loss after traumatic brain injury. Restor Neurol Neurosci 22:19-31.
Herzog AG (1999) Progesterone therapy in women with epilepsy, a 
3-year follow-up. Neurology 52:1917-1918.
Hirst JJ, Yawno T, Nguyen P, Walker DW (2006) Stress in pregnancy 
activates neurosteroid production in the fetal brain. Neuroendocri-
nology 84:264-274.
Ibanez C, Shields SA, El-Etr M, Baulieu EE, Schumacher M, Franklin RJ 
(2004) Systemic progesterone administration results in a partial re-
versal of the age-associated decline in CNS remyelination following 
toxin-induced demyelination in male rats. Neuropathol Appl Neuro-
biol 30:80-89.
Irwin RW, Brinton RD (2014) Allopregnanolone as regenerative thera-
peutic for Alzheimer’s disease: Translational development and clini-
cal promise. Prog Neurobiol 113:40-55.
Iwahashi K, Ozaki H S, Tsubaki M, Ohniski J, Taheuchi Y, Ichikawa Y 
(1990) Studies of the immunohistochemical and biochemical local-
ization of the cytochrome P-450-scclinked monooxygenase system in 
the adult rat brain. Biochem Biophys Acta 1035:182-189. 
21
Rey M, et al. / Neural Regeneration Research. 2015;10(1):17-21.
Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, 
Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert 
R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2002) Reversal 
of bone loss in mice by non genotropic signaling of sex steroids. Sci-
ence 298:843-846.
Kruse MS, Rey M, Barutta J, Coirini H (2009) Allopregnanolone effects 
on astrogliosis induced by hypoxia in organotypic cultures of stria-
tum, hippocampus and neocortex. Brain Res 1303:1-7.
Kruse MS, Rey M, Veleiro AS, Burton G, Coirini H (2010) Hypoxia 
impairs the morphology of neurons in cortex and hippocampus or-
ganotypic cultures. Biocell 34:A97.
Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA (2003) Neuroste-
roid modulation of GABAA receptors. Prog Neurobiol 71:67-80. 
Laurie DJ, Wisden W, Seeburg PH (1992) The distribution of thirteen 
GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and 
postnatal development. J Neurosci 11:4151-4172.
Majewska MD (1992) Neurosteroids: endogenous bimodal modulators 
of the GABAA receptor. Mechanism of action and physiological sig-
nificance. Prog Neurobiol 38:379-395.
Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) 
Steroid hormone metabolites are barbiturate-like modulators of the 
GABAA receptor. Science 232:1004-1007.
McCullers DL, Sullivan PG, Scheff SW, Herman JP (2002) Mifepristone 
protects CA1 hippocampal neurons following traumatic brain injury 
in rat. Neuroscience 109:219-230.
Melcangi RC, Froelichsthal P, Martini L, Vescovi AL (1996) Steroid 
metabolizing enzymes in pluripotential progenitor central nervous 
system cells: effect of differentiation and maturation. Neuroscience 
72:467-475.
Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG (2008) Neuroac-
tive steroids: state of the art and new perspectives. Cell Mol Life Sci 
65:777-797.
Mellon SH, Griffin LD, Compagnone NA (2001) Biosynthesis and ac-
tion of neurosteroids. Brain Res Brain Res Rev 37:3-12.
Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier 
G, Vaudry H (1999) Neurosteroids: expression of steroidogenic en-
zymes and regulation of steroid biosynthesis in the central nervous 
system. Pharmacol Rev 51:63-81. 
Morrow AL (2007) Recent developments in the significance and thera-
peutic relevance of neuroactive steroids-Introduction to the special 
issue. Pharmacol Ther 116:1-6. 
Nguyen PN, Yan EB, Castillo-Melendez M, Walker DW, Hirst JJ (2004) 
Increased allopregnanolone levels in the fetal sheep brain following 
umbilical cord occlusion. J Physiol 560:593-602.
Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almei-
da OF (1997) Neonatal treatment of rats with the neuroactive steroid 
tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral 
and neuroendocrine consequences of adverse early life events. J Clin 
Invest 99: 962-966.
Poisbeau P, Keller AF, Aouad M, Kamoun N, Groyer G, Schumacher 
M (2014) Analgesic strategies aimed at stimulating the endogenous 
production of allopregnanolone. Front Cell Neurosci 8:174. 
Purdy RH, Morrow AL, Blinn JR, Paul SM (1990) Synthesis, metabo-
lism, and pharmacological activity of 3α-hydroxy steroids which po-
tentiate GABA-receptor-mediated chloride ion uptake in rat cerebral 
cortical synaptoneurosomes. J Med Chem 33:1572-1581.
Qian M, Krishnan K, Kudova E, Li P, Manion BD, Taylor A, Elias G, 
Akk G, Evers AS, Zorumski CF, Mennerick S, Covey DF (2013) Neu-
rosteroid analogues. 18. Structure-activity studies of ent-steroid po-
tentiators of γ-aminobutyric acid type A receptors and comparison 
of their activities with those of alphaxalone and allopregnanolone. J 
Med Chem 57:171-190.
Rakotomamonjy J, Levenes C, Baulieu EE, Schumacher M, Ghoumari 
AM (2011) Novel protective effect of mifepristone on detrimental 
GABAA receptor activity to immature Purkinje neurons. FASEB J 
25:3999-4010.
Ramanjaneyulu R, Ticku MK (1984) Binding characteristics and inter-
actions of depressant drugs with [35S]t-butylbicyclophosphorothi-
onate; a ligand that binds to the picrotoxin site. J Neurochem 42:221-
229.
Reddy DS (2003) Is there a physiological role for the neurosteroid 
THDOC in stress-sensitive conditions? Trends Pharmacol Sci 24:103-
106.
Reddy DS (2010) Neurosteroids: endogenous role in the human brain 
and therapeutic potentials. Prog Brain Res 186:113-137.
Reddy DS, Kulkarni SK (1997) Differential anxiolytic effects of neu-
rosteroids in the mirrored chamber behavior test in mice. Brain Res 
752:61-71.
Reddy DS, Kulkarni SK (2000) Development of neurosteroid-base nov-
el psychotropic drugs. Prog Med Chem 37:135-175.
Reddy DS, Woodward R (2004) Ganaxolone, a prospective overview. 
Drugs Future 29:227-242. 
Rey M, Kruse MS, Alvarez LD, Ghini AA, Veleiro AS, Burton G, Coirini 
H (2013) Neuroprotective action of synthetic steroids with oxygen 
bridge. Activity on GABAA receptor. Exp Neurol 249:49-58.
Rheaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, 
Trudel C, Luu-The V, Simard J, Labrie F (1991) Structure and expres-
sion of a new complementary DNA encoding the almost exclusive 
3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in 
human adrenals and gonads. Mol Endocrinol 5:1147-1157.
Sanchez PE, Ryan MA, Kridelka F, Gielen I, Ren SG, Albertson B, Malo-
zowski S, Nieman L, Cassorla F (1989) RU-486 inhibits rat gonadal 
steroidogenesis. Horm Metab Res 21:369-371.
Schüle C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R 
(2011) Neuroactive steroids in affective disorders: target for novel 
antidepressant or anxiolytic drugs? Neuroscience 191:55-77.
Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari 
A, Gonzalez Deniselle MC, Gonzalez SL, Ibanez C, Labombarda F, 
Coirini H, Baulieu EE, De Nicola AF (2004) Local synthesis and dual 
actions of progesterone in the nervous system: neuroprotection and 
myelination. Growth Horm IGF Res 14:S18-S33. 
Vanover KE, Rosenzweig-Lipson S, Hawkinson JE, Lan NC, Belluzzi 
JD, Stein L, Barrett JE, Wood PL, Carter RB (2000) Characteriza-
tion of the anxiolytic properties of a novel neuroactive steroid, Co 
2-6749 (GMA-839; WAY-141839; 3alpha, 21-dihydroxy-3beta-tri-
fluoromethyl-19-nor-5beta-pregnan-20-one), a selective modulator 
of gamma-aminobutyric acid(A) receptors. J Pharmacol Exp Ther 
295:337-345.
Veleiro AS, Burton G (2009) Structure-activity relationships of neuro-
active steroids acting on the GABAA receptor. Curr Med Chem 16:1-
18.
Wang JM, Johnston PB, Ball BG, Brinton RD (2005) The neurosteroid 
allopregnanolone promotes proliferation of rodent and human neu-
ral progenitor cells and regulates cell-cycle gene and protein expres-
sion. J Neurosci 25:4706-4718.
Wang JM, Liu L, Irwin RW, Chen S, Brinton SD (2008) Regenerative 
potential of allopregnanolone. Brain Res Rev 57:398-409.
Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, 
Schumacher M, Delacourte A, Baulieu EE, Akwa Y (2002) Neuros-
teroid quantification in human brain regions: comparison between 
Alzheimer’s and nondemented patients. J Clin Endocrinol Metab 
87:5138-5143.
Weinfeld J, Siegel RA, Chowers I (1980) In vitro conversion of preg-
nenolone to progesterone by discrete brain areas of the male rat. J 
Steroid Biochem 13:961-963.
Wisden W, Laurie DJ, Monyer H, Seeburg PH (1992) The distribution 
of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telenceph-
alon, diencephalon, mesencephalon. J Neurosci 3:1040-1062.
Zwain IH, Yen SS (1999) Neurosteroidogenesis in astrocytes, oligoden-
drocytes, and neurons of cerebral cortex of rat brain. Endocrinology 
140:3843-3852.
